热门资讯> 正文
Neurobo Pharmaceuticals与Mthera Pharma签署独家许可协议
2024-07-30 20:51
- NeuroBo Pharmaceuticals (NASDAQ:NRBO) announced the signing of an exclusive license agreement, providing MThera Pharma Co with the rights to NB-01 for the treatment of painful diabetic neuropathy.
- The agreement allows MTHERA to conduct research and clinical trials, including, but not limited to, a potential Phase 3 clinical trial in the United States and South Korea, for the future commercialization of NB-01.
- Financial terms of the agreement were not disclosed.
- Source: Press Release
More on NeuroBo Pharmaceuticals
- NeuroBo Pharma prices private placement and direct offering to raise up to $70M
- NeuroBo says DA-1241, Wegovy combo shows potential in treating MASH
- Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals
- Historical earnings data for NeuroBo Pharmaceuticals
- Financial information for NeuroBo Pharmaceuticals
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
